Tag: BRILINTA

BRILINTA Approved in the US to Reduce the Risk of Stroke in Patients With an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Neuro by 0 comments

New indication expands use of BRILINTA beyond cardiovascular disease to patients with mild-to-moderate stroke WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s BRILINTA® (ticagrelor) has been approved in the US to reduce the risk of stroke, a leading cause of disability and death worldwide, in patients with acute ischemic stroke (National Institutes of Health Stroke Scale […]

Continue Reading →

BRILINTA Approved in the US to Reduce the Risk of a First Heart Attack or Stroke in High-Risk Patients with Coronary Artery Disease

Coronary/Structural Heart by 0 comments

New BRILINTA indication expands treatment to high-risk coronary patients without a history of stroke or heart attack WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca’s BRILINTA® (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with coronary artery disease (CAD), the most common type of […]

Continue Reading →

BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

Coronary/Structural Heart by 0 comments

BRILINTA monotherapy reduced bleeding complications with no increased risk of ischemic events in patients with diabetes undergoing percutaneous coronary intervention Consistent results were also observed in patients undergoing complex percutaneous coronary intervention WILMINGTON, Del.–(BUSINESS WIRE)–Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed BRILINTA (ticagrelor) […]

Continue Reading →